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Abstract
Vascular cell adhesion molecule-1 (VCAM-1) interacts with its major ligand very late antigen-4 (VLA-4) to mediate cell
adhesion and transendothelial migration of leukocytes. We report an important role for VCAM-1/VLA-4 interactions in the
generation of immune responses during experimental visceral leishmaniasis caused by Leishmania donovani. Our studies
demonstrate that these molecules play no direct role in the recruitment of leukocytes to the infected liver, but instead
contribute to IL-12p40-production by splenic CD8
+ dendritic cells (DC). Blockade of VCAM-1/VLA-4 interactions using whole
antibody or anti-VCAM-1 Fab9 fragments reduced IL-12p40 mRNA accumulation by splenic DC 5 hours after L. donovani
infection. This was associated with reduced anti-parasitic CD4
+ T cell activation in the spleen and lowered hepatic IFNc, TNF
and nitric oxide production by 14 days post infection. Importantly, these effects were associated with enhanced parasite
growth in the liver in studies with either anti-VCAM-1 or anti-VLA-4 antibodies. These data indicate a role for VCAM-1 and
VLA-4 in DC activation during infectious disease.
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Introduction
Very late antigen-4 (VLA-4; a4 integrin; CD49d) is expressed
on most leukocytes and plays an important role in leukocyte
trafficking by interacting with vascular cell adhesion molecule-1
(VCAM-1; CD106) on endothelial cells to mediate tethering,
rolling, firm adhesion and transendothelial migration [1,2]. This
interaction has also been implicated in the compartmentalisation
of B cells into peripheral lymphoid tissue [3], the association of
neutrophils with bone marrow (BM) stromal cells [4], the
promotion of interactions between follicular dendritic cells
(FDC) and B cells [5], and more recently, in the formation of a
docking structure that surrounds the B cell receptor (BCR) [6] and
TCR [7] in the immunological synapse (IS) that forms between
antigen presenting cells and antigen-specific B and T cells.
Visceral leishmaniasis (VL) caused by Leishmania donovani
infection in genetically susceptible C57BL/6 or BALB/c mice
results in parasite replication in the liver, spleen and BM [8]. The
liver is the site of an acute, resolving infection, associated with
leukocyte recruitment to infected resident Kupffer cells (KC) and
the subsequent generation of a localised inflammatory response
(granuloma formation), that includes the production of IFNc, TNF
and reactive oxygen and nitrogen species, necessary for killing
intracellular parasites [9–11]. In contrast, a chronic infection is
established in the BM and spleen, associated with major changes
to tissue architecture in the latter organ, including the loss of
marginal zone (MZ) macrophages and stromal cells in the
periarteriolar lymphoid sheath (PALS) [12,13]. Interestingly,
despite long-term parasite persistence in the spleen, this tissue is
an important site for early dendritic cell (DC) IL-12p40 production
that plays a key role in the generation of anti-parasitic immunity
required for the control of hepatic L. donovani replication [14–16].
We recently showed that VCAM-1 was expressed on hepatic
sinusoids during L. donovani infection in C57BL/6 mice. Further-
more, we demonstrated that VCAM-1 expression during infection
required lymphotoxin alpha (LTa) and that in LTa-deficient
C57BL/6 mice, the absence of VCAM-1 was associated with a
failure of leukocytes to migrate from periportal areas to infected
KC during granuloma formation, coincident with increased
parasite growth [17]. In this study, we investigated whether the
lack of VCAM-1 expression observed in L. donovani-infected mice
deficient in LTa could explain their failure to recruit leukocytes
into the liver and efficiently control parasite growth. Blockade of
VCAM-1 or VLA-4 suppressed anti-parasitic immune responses
and was associated with significantly higher hepatic parasite
burdens. However, rather than directly mediating cellular
recruitment to the liver during VL, our data indicate that
VCAM-1 and VLA-4 play a role in rapid CD8
+ DC IL-12p40
production in the spleen following L. donovani infection, an event
critical for the generation of effective anti-parasitic immunity.
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VCAM-1/VLA-4 interactions are critical for efficient
control of hepatic L. donovani infection
To investigate the role of VCAM-1 in VL, C57BL/6 mice were
administered anti-VCAM-1 mAb 5 hours prior to L. donovani
infection and then every third day thereafter until 14 days p.i.
Hepatic parasite burdens were significantly increased (p,0.01) in
these animals compared with rat IgG-treated controls at day 14
p.i. (Figure 1A). In addition, hepatic granuloma formation, an
important process for efficient control of L. donovani [9], was
significantly impaired in these mice with an increase in the
frequency of infected KC and a decrease in the frequency of
immature (IG) and mature granulomas (MG) (p,0.01; Figure 1B).
As expected, this was associated with a dramatic decrease (p,0.01)
in leukocyte recruitment to the liver following VCAM-1 blockade
(Figure 1C), with the recruitment of all leukocytes studied (CD4
+ T
cells, CD8
+ T cells, NKT cells, NK cells, B cells, macrophages/
monocytes, neutrophils and DC) being significantly and similarly
reduced (data not shown). IFNc, TNF and reactive nitrogen
intermediates (RNI; measured using nitric oxide synthase (NOS-2)
as a surrogate marker) are all critical for the control of L. donovani
infection [9–11,17], and mRNA encoding all of these molecules
was significantly reduced (p,0.05) in the livers of mice receiving
anti-VCAM-1 mAb (Figure 1D–F) at day 14 p.i. To confirm that
VLA-4 was the main integrin interacting with VCAM-1 during
VL, we also blocked this molecule using antibody over the first 14
days of infection, and obtained very similar results (Figure 2).
Together these data indicate that VCAM-1/VLA-4 interactions
play an important role in the generation of hepatic immune
responses following L. donovani infection.
VCAM-1/VLA-4 interactions do not play a direct role in
leukocyte recruitment to the liver following L. donovani
infection
To determine whether VCAM-1/VLA-4 interactions play a
direct role in cellular recruitment to the liver following L. donovani
infection, we delayed VCAM-1 or VLA-4 blockade until 3 days
after infection. We chose this time point to begin blockade because
no significant cellular recruitment to the liver had occurred before
this time (3.85610
664.48610
5 versus 4.22610
667.86610
5
hepatic leukocytes in naı ¨ve versus day 3 p.i. mice, respectively).
In contrast to blockade commenced prior to infection, this delayed
blockade failed to have any effect on parasite burden (Figure 3A),
the formation of granulomas (Figure 3B and C), or numbers of
hepatic mononuclear cells (MNC; Figure 3D), indicating that
VCAM-1/VLA-4 interactions played no role in leukocyte
recruitment to the liver. Therefore, the main role for VCAM-1/
VLA-4 interactions in VL appeared to be in the generation of
immune responses within the first 3 days of L. donovani infection.
Early DC IL-12p40 production in the spleen following L.
donovani infection
We have previously demonstrated that DC IL-12p40 produc-
tion in the spleen within 24 hours of L. donovani infection is critical
for the efficient generation of immunity in the liver [15,16].
However, the kinetics of DC IL-12p40 production, the relevance
of other infected tissue sites for the generation of this cytokine and
the specific DC sub-population responsible for IL-12p40 produc-
tion remain unknown. Therefore, we first measured IL-12p40
mRNA levels in the spleen, liver and BM, the main sites for L.
donovani infection, over the first 7 days of infection. We found that
IL-12p40 production occurred predominantly in the spleen and
peaked at 5 hours p.i. (Figure 4A). This pattern of production was
also confirmed by analysis of IL-12p40 protein expression in
spleen tissue sections (data not shown), as previously described
[15]. The IL-12p40-producing DC were located in the PALS, as
well in close proximity to the MZ (data not shown), as previously
reported [15,18]. To determine the specific DC subset producing
IL-12p40, MACS-enriched DC from naive mice and L. donovani-
infected mice 5 hours p.i., were labelled for CD11c, CD4 and
CD8a, and intracellular IL-12p40 protein levels were measured by
FACS. No IL-12p40 protein was detected in CD11c-negative cells
from either naı ¨ve or infected animals (data not shown), thereby
identifying DC as the main source of IL-12p40. Small numbers of
IL-12p40-producing CD11c
+ DC were observed in naı ¨ve mice
(Figure 4B). Five hours after L. donovani infection, there was a 2–3
fold increase in the number of IL-12p40-producing CD11c
+ DC,
and virtually all of the increased IL-12p40 production could be
attributed to the CD8
+ DC subset (Figure 4B). Together, these
data demonstrate that parasite-induced IL-12p40 is produced in
the spleen by CD8
+ DC within 5 hours of L. donovani infection.
VCAM-1 co-localises with sinusoidal endothelial cells and
MZ macrophages in close proximity with DC in the MZ of
the spleen
We next investigated where VCAM-1 was expressed in the
spleen to identify cell populations that might influence the
generation of immune responses to L. donovani infection, and in
particular CD8
+ DC IL-12p40 production. Studies in the mouse
spleen have reported VCAM-1 expression associated with
individual cells in the red pulp [19], within a broad zone in the
MZ [19] and within the B and T cell zones, including on follicular
dendritic cells [20]. We confirmed that the majority of VCAM-1
expression was in the red pulp region, and demonstrated that
expression could also be detected on discreet cell populations in
the MZ and white pulp (Figure 5A). In the red pulp, all F4/80
+
macrophages expressed VCAM-1 (Figure 5B). However, blood
flowing into the spleen is released into the marginal sinus before
flowing across the MZ into the red pulp and returning to the
circulation via a venous route [21], and the site where DC are first
likely to encounter parasites and/or parasite antigens is the MZ
[15,18]. In the MZ, there was little overlap observed between
staining for VCAM-1 and marginal metallophilic macrophages
Author Summary
VCAM-1 and its major ligand VLA-4 are adhesion molecules
required for the recruitment and movement of leukocytes
within tissue. In this study, we have investigated the role of
these molecules during an experimental infection with
Leishmania donovani, a protozoan parasite that causes a
chronic disease called visceral leishmaniasis. Surprisingly,
we showed that VCAM-1 and VLA-4 were not required for
leukocyte migration into the liver, a site of acute L.
donovani infection. Instead, there was a requirement for
these molecules to initiate cell-mediated immune respons-
es in the spleen within the first 5 hours of infection. When
VCAM-1 was blocked during infection, early dendritic cell
production of IL-12p40, a potent pro-inflammatory cyto-
kine required for control of L. donovani, was suppressed,
associated with a reduced parasite-specific T cell response
in the spleen, and impaired immunity and parasite
clearance in the liver. These results are important because
they identify a novel role for VCAM-1 and VLA-4 in the
regulation of dendritic cell activation during infectious
disease.
VLA-4 and VCAM-1 in VL
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+) (Figure 5B). In contrast, there was clear co-
localisation of VCAM-1 expression with MZ macrophages
(ERTR9
+/SIGNR1
+) (Figure 5C), and with sinusoidal endothelial
cells (Meca-32
+) located in the MZ (Figure 5D). Both VCAM-1
+
MZ macrophages and endothelial cells were located in close
proximity to discrete areas of DC (CD11c
+) (Figures 5C and D).
However, no clear VCAM-1 expression was observed on these DC
(Figures 5C and D), a finding also confirmed by FACS analysis of
VCAM-1 expression by splenic DC (data not shown). There was
some co-localisation of VCAM-1 with reticular fibroblasts (ER
TR7
+) throughout the spleen (data not shown). Isotype control
mAbs matched in concentration to each mAb did not show any
staining (not shown). These results indicate that the major VCAM-
1
+ cells found in the MZ where DC expressing VLA-4 are first
likely to contact parasites and/or parasite antigens are the
sinusoidal endothelial cells and MZ macrophages.
VCAM-1/VLA-4 interactions are not required for
lymphocyte or DC migration into the spleen
We next investigated whether VCAM-1 blockade modulated DC
and/or lymphocyte trafficking in the spleen following L. donovani
infection. Previous work showed that lymphocyte entry into the
spleen was not prevented by integrin blocking antibodies [3], and
we also confirmed this result by measuring migration of labelled
lymphocytes into the PALS following VCAM-1 blockade in naı ¨ve
animals and after 5 hours of L. donovani infection (data not shown).
However, the role of cell adhesion molecules in DC entry into the
spleen has not been previously investigated. Therefore, we
monitored migration of labelled DC into the spleen following
VCAM-1 blockade in naı ¨ve mice and after 5 hours of L. donovani
infection, but found no role for VCAM-1 in this process, regardless
whether mice were infected or not (Figure 6A–C). Therefore,
VCAM-1 blockade did not affect lymphocyte or DC migration into
Figure 1. VCAM-1 is required for efficient control of L. donovani infection in the liver. Female C57BL/6 mice were treated with anti-VCAM-1
mAb (closed bars) or control rat IgG (open bars) and infected with 2610
7 L. donovani amastigotes i.v. Mice were injected i.p. with 1 mg of antibody
prior to infection and every 3 days thereafter. Parasite burdens were determined in the liver at day 14 p.i. (A) and data represent the mean6SEM in
Leishman Donovan units. The number and maturity of hepatic granulomas were estimated on day 14 liver sections stained with anti-L. donovani sera
(B). Data represent the frequency of infected Kupffer cells (KC), immature granulomas (IG) and mature granulomas (MG) per liver. Hepatic
mononuclear cells were isolated from naı ¨ve (hatched bars) and infected mice on day 14 p.i. and enumerated (C). mRNA was extracted from livers of
naı ¨ve or day 14 p.i. VCAM-1 blocked or control mice, and accumulation of IFNc (D), TNF (E) and NOS-2 (F) mRNA was detected by real-time RT-PCR
and is expressed as mRNA molecule per 1000 HPRT molecules. One representative experiment of two performed with similar outcome is shown (n=4
mice per treatment group in each experiment). Statistical differences of p#0.05 (*) or p,0.01 (**) for control versus anti-VCAM-1 treatment are
indicated.
doi:10.1371/journal.ppat.1000158.g001
VLA-4 and VCAM-1 in VL
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cell movement between distinct regions within the spleen.
VCAM-1/VLA-4 interactions play a critical role in splenic
DC IL-12p40 production
To test whether VCAM-1/VLA-4 interactions play a direct role
in DC IL-12p40 production, we blocked these molecules 12 hours
prior to infection and measured IL-12p40 mRNA levels in DC
isolated from the spleen at 5 hours p.i. (Figure 7A). In control-
treated mice, DC IL-12p40 mRNA levels increased 2–3 fold
5 hours after L. donovani infection. VCAM-1 blockade inhibited
50–100% of DC IL-12p40 mRNA accumulation, while VLA-4
blockade reduced DC IL-12p40 mRNA levels by 50–90% (n=4
experiments).
However, given the co-localisation of DC with VCAM-1
+ cells
in the spleen (Figure 5), it is possible that the ligation of Fcc
receptors (FccR) on DC by anti-VCAM-1 mAbs could suppress
IL-12p40 production, as previously reported for human and
mouse DC [22,23]. Therefore, we next generated anti-VCAM-1
Fab9 fragments that comprised the antigen binding region of the
mAb, but have all FccR binding domains removed, and hence, are
unable to signal via FccR. Splenic DC isolated from mice treated
with control rat IgG Fab9 fragments 5 hours after L. donovani
infection had a significant accumulation of IL-12p40 mRNA,
relative to DC from naı ¨ve mice (Figure 7B). Importantly, IL-12p40
accumulation in splenic DC from mice treated with anti-VCAM-1
Fab9 fragments was significantly reduced (p,0.01), compared with
DC from control-treated mice (Figure 7B). The reduction of IL-
12p40 mRNA accumulation with anti-VCAM-1 Fab9 fragments
was not as effective as with anti-VCAM-1 mAb, and this most
likely reflects the very short half-life of Fab9 fragments in plasma
(around 1 hour) compared with mAbs (hours-days), and their
rapid excretion by the kidney [24,25]. Nevertheless, these data
support the conclusion that specific blockade of VCAM-1 reduces
Figure 2. VLA-4 is required for efficient control of L. donovani infection in the liver. Female C57BL/6 mice were treated with anti-VLA-4
mAb (closed bars) or control rat IgG (open bars) and infected with 2610
7 L. donovani amastigotes i.v. Mice were injected i.p. with 1 mg of antibody
prior to infection and every 3 days thereafter. Parasite burdens were determined in the liver at day 14 p.i. (A) and data represent the mean6SEM in
Leishman Donovan units. The number and maturity of hepatic granulomas was estimated on day 14 liver sections stained with anti-L. donovani sera
(B). Data represent the frequency of infected Kupffer cells (KC), immature granulomas (IG) and mature granulomas (MG) per liver. Hepatic
mononuclear cells were isolated from naı ¨ve (hatched bars) and infected mice on day 14 p.i. and enumerated (C). mRNA was extracted from livers of
naı ¨ve (hatched bars) or day 14 p.i. VLA-4 blocked (closed bars) or control mice (open bars), and accumulation of IFNc (D), TNF (E) and NOS-2 (F) mRNA
was detected by real-time RT-PCR and is expressed as mRNA molecule per 1000 HPRT molecules. One representative experiment of two performed
with similar outcome is shown (n=4 mice per treatment group in each experiment). Statistical differences of p,0.05 (*) or p,0.01 (**) for control
versus anti-VLA-4 treatment are indicated.
doi:10.1371/journal.ppat.1000158.g002
VLA-4 and VCAM-1 in VL
PLoS Pathogens | www.plospathogens.org 4 September 2008 | Volume 4 | Issue 9 | e1000158DC IL-12p40 mRNA accumulation following L. donovani infection,
and that this effect of anti-VCAM-1 mAb treatment was not
caused by FccR ligation on DC.
To confirm that parasite-induced IL-12p40 mRNA accumula-
tion in CD8
+ DC was the main target of VCAM-1 blockade, we
next sorted these cells following MACS enrichment, based on
expression of CD11c, MHC-II and CD8a (Figure 7C), from naı ¨ve
animals or at 5 hours p.i. from mice infected with L. donovani that
had received control rat IgG or anti-VCAM-1 mAb prior to
infection. As expected, the majority of IL-12p40 mRNA
accumulation occurred in CD8
+ DC, and levels increased
approximately 2-fold at 5 hours p.i. Importantly, this increase
did not occur in CD8
+ DC from mice in which VCAM-1 had
been blocked (Figure 7D). There was some disparity between IL-
12p40 mRNA accumulation (Figure 7D) and IL-12p40 protein
levels (Figure 4B) in different DC subsets from naı ¨ve mice,
whereby virtually all IL-12p40 mRNA accumulated in CD8
+ DC,
but IL-12p40 protein expression was similar between DC subsets.
This may reflect different rates of IL-12p40 mRNA turnover or
protein retention in different splenic DC subsets. We also observed
that a small proportion of CD8
+ DC were infected with L. donovani
amastigotes at 5 hours p.i., and that infection of these cells was not
reduced by anti-VCAM-1 mAb (0.5060.10% versus 0.3760.11%
for mice receiving rat IgG or anti-VCAM-1 mAb, respectively,
determined from cytospins).
Our data indicate that VCAM-1/VLA-4 interactions are
important for splenic CD8
+ DC IL-12p40 production 5 hours
after L. donovani infection, and that this is important for the efficient
generation of anti-parasitic T cell responses required for control of
hepatic infection. To directly examine whether L. donovani-specific
CD4
+ T cell activation was affected by blockade of VCAM-1/
VLA-4 interactions, we next isolated splenic CD4
+ T cells at day
14 p.i., and re-stimulated them in vitro in the presence of naı ¨ve,
irradiated APC and fixed L. donovani amastigotes. There was little
proliferation of splenic CD4
+ T cells from naı ¨ve animals in
response to parasite antigen (Figure 7E). However, significant
parasite-specific proliferation was observed in CD4
+ T cells from
control-treated mice, but this was significantly reduced in CD4
+ T
cell from animals that had received either anti-VCAM-1 or anti-
VLA-4 mAbs (Figure 7E). There was no difference in CD4
+ T cell
proliferation in response to concanavalin A in any of the groups
tested, indicating that blockade of VCAM-1/VLA-4 did not
generally suppress or inactivate CD4
+ T cells. Together, these data
indicate that CD8
+ DC require VCAM-1/VLA-4 interactions for
IL-12p40 production, associated with the generation of effective
anti-parasitic CD4
+ T cell responses required for the control of L.
donovani growth in the liver.
Discussion
The interaction between VCAM-1 and VLA-4 appears to be
important for the outcome of hepatic L. donovani infection.
However, these molecules play no role in the recruitment of
leukocytes to the infected liver during VL, and there appears to be
no clear role for LTa-dependent VCAM-1 expression on hepatic
sinusoids. Instead, VCAM-1/VLA-4 interactions modulate IL-
12p40 production by CD8
+ DC in the spleen within hours of
parasite challenge. Blockade of VCAM-1, along with its
physiological ligand VLA-4, resulted in reduced IL-12p40
production by CD8
+ DC. Studies with anti-VCAM-1 Fab9
fragments also indicate a role for VCAM-1/VLA-4 interactions
in DC IL-12p40 production. Blockade of VCAM-1 with
antibodies was also associated with reduced CD4
+ T cell
proliferation in the spleen and impaired resistance to L. donovani
in the liver. The spleen harbours a relatively low parasite burden
at the early time points assessed in this study, and this was not
affected by VCAM-1 or VLA-4 blockade (data not shown).
DC IL-12p40 production shortly after L. donovani infection plays
a key role in the generation of anti-parasitic immune mechanisms
and is critical for the effective control of VL [14,16]. Recently,
both IL-12p70 and IL-23, each utilising the IL-12p40 subunit,
were found to be functionally important cytokines for the control
of L. donovani infection [26]. We have demonstrated that splenic
CD8
+ DC are the major source of IL-12p40 following L. donovani
infection, and that parasite-induced IL-12p40 production occurs
transiently, peaking 5 hours after infection (Figure 4). This early
IL-12p40 production is physiologically important because when it
is blocked during the first 24 hours of infection there is a failure to
effectively control parasite growth in the liver and spleen [16].
The location of DC in the spleen is important during this early
phase of infection and DC are required to migrate from the MZ
into the PALS within the first 5 hours of infection in order for
efficient T cell priming and maximal IL-12p40 production to
occur [18]. This pattern of cell movement supports a model
whereby parasites are rapidly taken up by macrophages in the MZ
[15,18], parasite antigen is then either transferred from these cells
to DC or the DC directly acquire antigen in the MZ, and
Figure 3. VCAM-1/VLA-4 interactions are not required for
leukocyte migration into the liver following L. donovani
infection. Female C57BL/6 mice were untreated (vertical hatched
bar) or treated with anti-VCAM-1 mAb, anti-VLA-4 mAb (closed bars) or
control rat IgG (open bars) and infected with 2610
7 L. donovani
amastigotes i.v. Mice were injected i.p. with 1 mg of antibody prior to
infection and every 3 days thereafter (black bars), or starting from day 3
and every 3 days thereafter (grey bars). Parasite burdens were
determined in the liver at day 14 p.i. (A) and data represent the
mean6SEM in Leishman Donovan units. The number and maturity of
hepatic granulomas was estimated on day 14 liver sections labelled
with anti-L. donovani sera from VLA-4 blocked mice (B) and VCAM-1
blocked mice (C). Data represent the frequency of infected Kupffer cells
(KC), immature granulomas (IG) and mature granulomas (MG) per
mouse. Hepatic MNC were isolated from naı ¨ve (hatched bars) and
infected mice on day 14 p.i. and enumerated (D). One representative
experiment of two performed with similar outcome is shown (n=4
mice per treatment group in each experiment). Statistical differences of
p,0.01 (**) for control versus anti-VCAM-1 or anti-VLA-4 treatment are
indicated.
doi:10.1371/journal.ppat.1000158.g003
VLA-4 and VCAM-1 in VL
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suggest that VLA-4/VCAM-1 interactions play a role in these
events. Blockade of VCAM-1 did not affect splenic parasite
burden in the first 24 hours of L. donovani infection (data not
shown), suggesting that VLA-4/VCAM-1 interactions play no role
in parasite uptake by macrophages. In addition, the acquisition of
parasites by CD8
+ DC was not prevented by VCAM-1 blockade.
Histological examination of spleen tissue indicated that red pulp
macrophages were the main VCAM-1
+ cell population in the
spleen (Figures 5A and B). However, these cells are spatially
segregated from the IL-12p40-producing DC found in the MZ
and T cell zones. In the MZ, sinus lining endothelial cells and MZ
Figure 4. IL-12p40 is produced rapidly and transiently in the spleen by CD8
+ DC following L. donovani infection. (A) Mice were infected
with 2610
7 L. donovani amastigotes i.v. and sacrificed at 2 hr, 5 hr, 12 hr, 24 hr, 72 hr, 5 days and 7 days p.i. mRNA was extracted from the spleen
(squares), liver (inverted triangles) and bone marrow (triangles) at each time point and accumulation of IL-12p40 mRNA was detected by real-time RT-
PCR and is expressed as mRNA molecule per 1000 HPRT molecules. Data are representative of 3 mice per time point. (B) Mice were infected with
1610
8 L. donovani amastigotes i.v. and spleens were removed at 5 hr p.i. MACS-enriched DC were enumerated by labelling with anti-CD11c mAb and
examined for expression of isotype control mAb or IL-12p40 (1,000,000 events collected, 10,000 events shown). Cells were then electronically gated,
based on expression of IL-12p40, as indicated, and then examined for expression of CD4 and CD8 (5000 events shown). Gates were determined from
an isotype control for IL-12p40, in which 0.8% of CD11c
+ cells were shown to be positive. Numbers below rectangular gates indicate the percentage
of cells in that gate, while numbers in the upper right hand corners of FACS profiles indicate the percentage of cells in the indicated quadrants. One
representative experiment of three performed with similar outcome is shown (n=4 mice per treatment group in each experiment).
doi:10.1371/journal.ppat.1000158.g004
VLA-4 and VCAM-1 in VL
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close proximity to DC (Figures 5C and D). VCAM-1 on
endothelium can mediate cell adhesion and transendothelial
migration [1,2], and early in L. donovani infection endothelial
VCAM-1 may be involved in either the adhesion of DC in the MZ
or the movement of these cells into the PALS after antigen
acquisition. However, previous work has shown that lymphocyte
entry into the spleen is not prevented by blocking any single
integrin, including VLA-4 [3], and we also observed no effect of
VCAM-1 blockade on lymphocyte trafficking (data not shown) or
on the retention of labelled naı ¨ve DC in the spleen in naı ¨ve
animals and 5 hours after L. donovani infection (Figure 6).
Therefore, a role for VCAM-1-mediated naı ¨ve DC retention in
the MZ is unlikely.
The other main VCAM-1
+ cell population in the MZ were the
MZ macrophages (Figure 5C). These cells are highly phagocytic
and rapidly take up L. donovani after infection [15,18]. Further-
more, these cells are lost from the spleen after a chronic infection
becomes established (day 21–28 p.i.) via a TNF-dependent
mechanism, disrupting cellular movement in this organ [12].
Therefore, VCAM-1 on MZ macrophages could mediate DC
movement from the MZ into the PALS. Alternatively, it could
mediate interactions between DC and MZ macrophages, allowing
uptake of parasite antigen by DC and/or activation of DC.
Attempts to adoptively transfer splenic DC (5610
6) isolated from
mice 5 hours post-L. donovani infection (time of peak IL-12p40
production) to mice receiving VCAM-1 blockade, thereby
bypassing these early cellular interactions, failed to improve
Figure 5. VCAM-1 expression in the spleens of naive C57BL/6 mice. (A) VCAM-1 localisation (green) in a tissue section from a naı ¨ve mouse.
Marginal metallophilic macrophages were stained with MOMA-1 mAb (red) allowing visualisation of red pulp (RP), white pulp (WP) and marginal zone
(MZ) regions of the spleen, as indicated (6100) The tissue section was mounted in media containing DAPI to stain cell nuclei (blue). (B-D) Staining for
VCAM-1 expression, red pulp macrophages (F4/80
+), MM macrophages (MOMA-1
+), MZ macrophages (ERTR9/SIGNR1
+), MZ sinus-lining endothelial
cells (Meca-32
+) and DC (CD11c
+)( 6630) is shown in colours indicated above panels. White arrows in (C) and (D) indicate areas where VCAM-1
+ cells
(yellow) are in close proximity to DC (blue).
doi:10.1371/journal.ppat.1000158.g005
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shown). Although this result suggests that later cellular interactions
might be VCAM-1 dependent, only a small proportion of
transferred DC (less than 10%) were found in the spleen 24 hours
after transfer. Therefore, we cannot exclude the possibility that the
failure to overcome VCAM-1 blockade resulted from altered DC
trafficking caused by infection or the fact that DC from infected
mice are unable to traffic effectively back to the T cell zones within
the spleen.
VLA-4 has also been localised at the centre of the peripheral
supramolecular activation complex (pSMAC) that surrounds the
TCR-peptide-MHC complexes localised at the centre of the
SMAC in the IS [7]. We failed to detect VCAM-1 expression by
DC in the spleen either prior to or during infection, thus
questioning the potential for VLA-4/VCAM-1 interactions in the
SMAC of any IS that formed between DC presenting parasite
antigen and L. donovani-specific T cells in the spleen after infection.
However, we cannot rule out the possibility that physiologically
relevant VCAM-1 expression on splenic DC is present, but
beyond the detection limits of the histological and FACS methods
we have employed. All conventional DC subsets in the spleen are
capable of T cell activation, and the CD8
+ DC isolated from L.
donovani-infected mice 5 hours p.i. promote IL-12/23p40-depen-
dent skewing towards IFNc production by responding CD4
+ T
cells [27]. In addition, the CD8
+ DC are capable of acquiring L.
donovani amastigotes independent of VCAM-1 early after infection,
and these infected cells are able to produce IL-12p40 (Maroof,
unpublished). Our data also indicate that VCAM-1/VLA-4
interactions play an important role in the priming of parasite-
specific CD4
+ T cells.
Short-term (5 hr) experiments with anti-VCAM-1 Fab9 frag-
ments suggested that FccR ligation on DC was not responsible for
the observed reduced DC IL-12p40 production. However,
blockade of VCAM-1 and the reduction of DC IL-12p40 with
Fab9 fragments was not as effective as whole mAb, perhaps due to
their extremely short half-life and rapid excretion by the kidney
due to their low molecular weight [24,25]. Ideally we would have
liked to confirm our results at day 14 with Fab9 fragments, as well
as whole mAb. However, it would not be possible to interpret the
results of such long-term experiments accurately due to the
limitations discussed above.
In conclusion, we have shown that VCAM-1/VLA-4 interac-
tions modulate CD8
+ DC IL-12p40 production and may play a
role in the activation of parasite-specific CD4
+ T cells during
Figure 6. VCAM-1/VLA-4 interactions are not critical for DC migration into the spleen. Naı ¨ve C57BL/6 mice were injected with 100 mg
FITC-dextran i.v. followed by 1 mg of control rat IgG (A) or anti-VCAM-1 mAb (B) i.p. 24 hr later. Hoechst 33342-labelled splenic CD11c
+ DC (1610
6)
were administered i.v. 1 hr following mAb injection. The following day mice were either left as naı ¨ve or infected with 2610
7 L. donovani amastigotes
i.v. and spleens were removed 5 hr later (24 hr post-cell transfer). The distribution of Hoechst 33342-labelled cells was analysed in 20 mm sections and
photographed under UV illumination (6100). Data are representative of one of two experiments performed (n=3 mice per group). The number of
Hoechst 33342-labelled cells was determined from 15 fields of view per mouse spleen (625 magnification) (C).
doi:10.1371/journal.ppat.1000158.g006
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+ DC. (A) C57BL/6 mice
were treated with 1 mg anti-VCAM-1 mAb, anti-VLA-4 mAb or control rat IgG or (B) with 1 mg anti-VCAM-1 Fab fragments or control rat IgG Fab
fragments the day prior to infection with 1610
8 L. donovani amastigotes. CD11c
+ DC were enriched by positive selection by MACS from the spleens
of naı ¨ve mice (hatched bars), or antibody treated mice (closed bars) or control treated mice (open bars) at 5 hr p.i. mRNA was extracted from MACS-
enriched DC, and accumulation of IL-12p40 mRNA was detected by real-time RT-PCR. One representative experiment of four performed with similar
outcome is shown (n=4 mice per treatment group in each experiment). All data is expressed as IL-12p40 mRNA molecules per 1000 HPRT molecules.
(C–D) MACS-enriched CD11c
+ DC from naı ¨ve C57BL/6 mice (hatched bars) or L. donovani-infected mice at 5 hr p.i. treated with either control rat IgG
(open bars) or anti-VCAM-1 (closed bars), were sorted based on CD11c and MHC-II expression, followed by separation into CD8a-positive and CD8a-
negative populations. Percentages of each gated population are indicated. (D) mRNA was extracted from purified CD8
+ or CD8
2 DC populations, as
indicated, and accumulation of IL-12p40 mRNA was detected by real-time RT-PCR. Data represent groups of pooled cells from 4 mice, repeated 3
times. (E) Proliferation of splenic CD4
+ T cells from naı ¨ve (hatched bars) or L. donovani-infected C57BL/6 mice (day 14 p.i.) that had received anti-
VCAM-1 mAb, anti-VLA-4 mAb (closed bars) or control rat IgG (open bars), as indicated, in the presence of naı ¨ve irradiated splenic APC pulsed with
fixed L. donovani amastigotes. One representative experiment of two performed with similar outcome is shown (n=4 mice per treatment group in
each experiment). Data is presented as a stimulation index (SI) calculated by dividing the proliferation of each sample in response to parasite antigen
by proliferation in culture media alone. Statistical differences of p,0.01 (**) for antibody versus control treated mice are indicated.
doi:10.1371/journal.ppat.1000158.g007
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are not directly involved in cellular recruitment to the liver during
VL. These findings advance our understanding of the induction of
cell-mediated immune responses following pathogen challenge,
and identify a potential target for modulation to either enhance or
suppress inflammation during disease.
Materials and Methods
Mice
Inbred female C57BL/6 and BALB/c mice were purchased
from the Australian Resource Centre (Canning Vale, Western
Australia), and maintained under conventional conditions. All
mice used were age-matched (6 to 10 weeks), and were housed
under specific-pathogen free conditions. All animal procedures
were approved and monitored by the Queensland Institute of
Medical Research Animal Ethics Committee.
Parasites and infection of mice
L. donovani (LV9) was maintained by passage in BALB/c or
B6.RAG-1
2/2 mice, and amastigotes were isolated from the
spleens of chronically infected mice. Mice were infected by
injecting 2610
7 amastigotes intravenously via the lateral tail vein,
killed at the times indicated in the text by CO2 asphyxiation and
bled via cardiac puncture. In experiments examining DC IL-
12p40 protein production, mice were infected with 1610
8
amastigotes intravenously, as previously reported [15,18,27].
Spleens and perfused livers were removed and parasite burdens
were determined from Diff-Quick-stained impression smears (Lab
Aids, Narrabeen, Australia), and expressed in Leishman-Donovan
units (the number of amastigotes per host nuclei multiplied by the
organ weight) [28]. Liver and spleen tissue were also preserved in
either RNAlater (Sigma-Aldrich, Castle Hill, Australia) or Tissue-
Tek O.C.T. Compound (Sakura, Torrance, USA). Hepatic
mononuclear cells (MNC) were isolated immediately following
death as previously described [17].
VCAM-1 and VLA-4 blockade
Anti-VCAM-1 (MK2/7; CRL-1909, rat IgG1) [29] and anti-
VLA-4 (P/S2; CRL-1911, rat IgG2b) [30] hybridomas were
purchased from the American Type Culture Collection (Manassas,
VA). Purified antibody was prepared from culture supernatants by
protein G column purification (Amersham, Uppsala, Sweden)
followed by endotoxin removal (Mustang membranes, Pall, East
Hills, NY). For VCAM-1 and VLA-4 blockade, C57BL/6 mice
were injected i.p. with 1 mg of appropriate mAb or purified
control rat IgG (Sigma-Aldrich) on the day of infection and every
three days thereafter, or as detailed in the text. This dosing regime
was based on one previously used in a collagen-induced arthritis
model [31], except that 0.5 mg doses were used in this study. In
our hands, 0.5 mg doses only achieved partial blockade of DC IL-
12p40mRNA accumulation and hepatic anti-parasitic immunity,
compared with 1 mg doses, hence our use of the increased
amounts of mAb. We also found that the anti-VLA-4 mAb could
be detected on the surface of splenic lymphocytes for at least
72 hours following injection of 1 mg into naı ¨ve mice (data not
shown). Anti-VCAM-1 mAb and control rat IgG Fab fragments
were generated using a commercial kit according to the
manufacturer’s instructions (Thermo Scientific, Rockford, IL).
Histological response to hepatic infection
Acetone-fixed liver sections (6 mm) were labelled with hamster
antisera to L. donovani amastigotes at a dilution of 1 in 1000.
Labelling was detected with a biotinylated goat anti-hamster
antibody (Vector Laboratories, Burlingame, CA). Sections were
developed with Vector-Elite ABC kit, followed by 3,39-diamino-
benzidine substrate kit (Vector Laboratories). Granuloma density
was determined from 25 fields of view per mouse liver (640
magnification), and the maturation of granulomas was scored
around infected Kupffer cells, as described elsewhere [32].
Isolation of DC
Spleens were digested in collagenase type IV (1 mg/ml;
Worthington, Lakewood, NJ) and deoxyribonuclease I (0.5 mg/
ml; Worthington) at room temperature for 45 minutes. Spleno-
cytes were isolated by passing digested spleens through a 100 mm
cell strainer, followed by red blood cell lysis (Sigma-Aldrich).
CD11c
+ DC were positively selected from splenocyte preparations
using magnetic-activated cell sorting (MACS) with metallo-
conjugated anti-mouse CD11c antibodies (N418) and positive
selection columns, according to the manufacturer’s instructions
(Miltenyi Biotec, Bergisch Gladbach, Germany). In some exper-
iments, following MACS enrichment, DC were sorted into CD8a-
positive and CD8a-negative populations by labelling with
antibodies to CD11c, MHC-II and CD8a, and sorting on a
MoFlo Cell Sorter (Dako, Botany, NSW, Australia), as shown in
Figure 7.
Flow cytometry
Liver MNC or splenocytes were harvested and pre-incubated
with CD16/32 mAb (2.4G2; grown in-house) to avoid non-specific
binding of antibodies to FccR. For the staining of cell surface
antigens, cells were incubated with fluorochrome-conjugated or
biotinylated mAbs on ice for 30 minutes followed by streptavidin
incubation for an additional 30 minutes when required. T cells,
NKT cells and NK cells were enumerated with allophycocyanin
(APC)-conjugated anti-TCRb chain (H57-597), fluorescein iso-
thiocyanate (FITC)-conjugated anti-CD4 (GK1.5), phycoerythrin
(PE)-conjugated anti-CD8a (H1.2F3), and biotinylated anti-
NK1.1 (PK136). B cells were enumerated using FITC-conjugated
anti-CD19 (6D5) and APC-conjugated anti-B220 (RA3-6B2). DC
were enumerated with APC-conjugated anti-CD11c (N418) and
FITC- or PE-conjugated anti-I-A/I-E (MHC-II; M5/114.15.2).
All mAbs were purchased from Biolegend (San Diego, CA) or BD
Biosciences (Franklin Lakes, NJ). Rat anti-mouse CR3 (5C6) and
rat anti-mouse GR-1 (RB6 8C5) were grown and biotinylated in
house, and used to enumerate monocytes and granulocytes,
respectively. Biotinylated antibodies were detected using Alexa
Fluor 488-conjugated streptavidin (Invitrogen Life Technologies,
Mount Waverley, Australia). Flow cytometric analysis was
performed on a FACScalibur flow cytometer and analysed using
Cell Quest Pro Software (BD Biosciences). For intracellular IL-
12p40 staining, splenocytes were incubated for 4 hours at 37uCi n
10% (v/v) foetal calf serum, RPMI containing 10 mg/ml brefeldin
A (Sigma-Aldrich) prior to cell surface labelling with antibodies to
CD11c, CD8a and CD4 (all from BD Biosciences). Cells were
then washed and fixed in 1% (w/v) paraformaldehyde, before
being washed in FACS buffer containing 0.1% (w/v) saponin
(BDH, Lutterworth, UK) and stained with PE-conjugated anti-IL-
12p40 (C15.6) or an isotype control mAb (both from BD
Biosciences).
DC cytospins
Sorted CD8
+ and CD8
2 DC (1610
5) in 100 ml FACS buffer
were collected onto a glass slide using a Cytospin 3 centrifuge,
according to the manufacturer’s instructions (Shandon Scientific
Ltd, Cheshire, UK), prior to staining with Diff-Quick (Lab Aids) to
visualise host cell and parasite nuclei microscopically.
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Reaction
Total RNA was extracted from bone marrow, spleen or liver
tissue using TRIzol reagent (Invitrogen Life Technologies), and an
RNeasy Mini Kit with on-column DNase digestion (Qiagen,
Valencia, CA). Total RNA was extracted from purified DC using
an RNeasy Mini Kit with on-column DNase digestion (Qiagen),
according to the manufacturer’s instructions. RNA samples were
reverse transcribed into cDNA using the cDNA Archive Kit
(Applied Biosystems, Foster City, CA) according to the manufac-
turer’s instructions. The number of IFNc, TNF and NOS-2 cDNA
molecules in each sample were calculated using Taqman Gene
Expression Assays (Applied Biosystems), and the number of IL-
12p40 (59 CTTGCAGATGAAGCCTTTGAAGA (forward) and
59 GGAACGCACCTTTCTGGTTACA (reverse)), and HPRT
(59 GTTGGATACAGGCCAGACTTTGTTG (forward) and
59GATTCAACCTTGCGCTCATCTTAGGC (reverse)) (house-
keeping gene) cDNA molecules in each sample were calculated by
real-time reverse transcriptase-polymerase chain reaction (rtPCR)
using Platinum Sybr Green Master Mix (Invitrogen Life
Technologies). All real-time reverse transcriptase-polymerase
chain reactions (rtPCR) were performed on a Corbett Research
RG-3000 Rotor Gene (Corbett Life Sciences, Sydney, Australia).
Standard curves were generated with known amounts of cDNA for
each gene, and the number of cytokine molecules per 1000 HPRT
molecules in each sample was calculated.
Lymphocyte and DC trafficking experiments
Mice were pre-injected with 100 mg FITC-dextran i.v. (200,000
MW, anionic, Invitrogen Life Technologies) to label marginal zone
macrophages, followed by 1 mg of anti-VCAM-1 or rat IgG control
antibody i.p. 24 hours later. Lymphocytes were isolated from naı ¨ve
splenocytes using Histopaque 1083 (Sigma), according to the
manufacturer’s instructions. Splenic lymphocytes or CD11c
+ DC
were labelled with Hoechst 33342, as described previously [12].
Mice were administered with 1610
7 Hoechst 33342-labelled
lymphocytes or 1610
6 Hoechst 33342-labelled DC via the lateral
tail vein 1 hour post mAb injection. Mice were sacrificed 3 hours
following lymphocyte transfer and 24 hr following DC transfer, and
spleens were removed and embedded in Tissue-Tek O.C.T.
compound (Sakura). The distribution of Hoechst 33342-labelled
cells was analysed in 20 mm sections mounted in Pro-long Gold
anti-fade (Invitrogen Life Technologies) using a Carl Zeiss inverted
fluorescent microscope under UV illumination.
Confocal microscopy
Tissue-Tek O.C.T. compound-preserved sections (6 mm) of
spleen tissue were acetone fixed and labelled with anti-VCAM-1
(429; MVCAM.A, BD Bioscience) detected by direct conjugation
to Alexa Fluor 647 using a monoclonal antibody labelling kit, or
with a fluorochrome conjugated goat anti-rat antibody (both from
Invitrogen Life Technologies). To identify cell populations the
sections were then labelled with different combinations of rat
antibodies to murine metallophilic macrophages (MOMA-1, Acris
Antibodies, Hiddenhausen, Germany), marginal zone (MZ)
macrophages (ERTR9, specific ICAM-3-grabbing nonintegrin-
related 1 (SIGNR1), Bachem Ltd. Merseyside, UK), reticular
fibroblasts (ERTR7, BMA Biomedicals, Augst, Switzerland),
endothelial cells (Meca-32, BD Biosciences), FITC -conjugated
CD11c (BD Biosciences) and Alexa Fluor 647-conjugated F4/80
(BD Biosciences). Fluorochrome conjugated goat anti-rat antibod-
ies were used for detection of purified antibodies. Sections were
mounted in Pro-long Gold anti-fade (Invitrogen Life Technologies)
and visualized using a Carl Zeiss inverted LSM META 510
confocal microscope.
Antigen re-stimulation of splenic CD4
+ T cells
Splenic CD4
+ T cells were positively selected by MACS from
splenocytes using metallo-conjugated anti-CD4 antibodies and
positive selection columns, according to the manufacturer’s instruc-
tions (Miltenyi Biotec). CD4
+ T cells (5610
4 cells per well) were
stimulated with 2610
6 paraformaldehyde-fixed L. donovani amasti-
gotes,and 1610
6irradiated, naı ¨veC57BL/6spleen cellsat 37uC, 5%
(v/v) CO2. After 72 hours of culture, cells were pulsed with 1 mCi
[
3H] thymidine for 18 hours, prior to measuring thymidine
incorporation using a Betaplate reader, (Wallac, Turku, Finland).
Statistical analysis
The statistical significance of differences between groups was
determined using a Mann Whitney test or an unpaired Student’s t
test using GraphPad Prism version 4.03 for Windows (GraphPad
Software, San Diego, CA) and p,0.05 was considered statistically
significant. The distribution of hepatic histological responses were
compared using X
2 analysis with Microsoft Excel software. All
data are presented as the mean values6standard errors unless
otherwise stated.
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